Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

NCT01028859 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: CKD-516 inj

Sponsor

Chong Kun Dang Pharmaceutical

Collaborators

[object Object]